S.Korea
secures 20,000 courses of Merck's COVID-19 pill, says PM
Send a link to a friend
[October 06, 2021]
By Sangmi Cha
SEOUL (Reuters) - South Korea has secured
20,000 courses of an experimental antiviral pill developed by Merck & Co
for COVID-19 treatment, Prime Minister Kim Boo-kyum said on Wednesday,
joining other Asian nations rushing to snap up supplies.
|
Merck also announced on Wednesday a supply and purchase agreement
with Singapore
https://www.reuters.com/
business/healthcare-pharmaceuticals/
merck-says-deal-signed-with-singapore-covid-19-antiviral-pill-2021-10-06,
following Australia https://www.reuters.com/world/asia-pacific/australia-buy-300000-doses-mercks-covid-19-antiviral-pill-2021-10-04,
while Thailand, Taiwan and Malaysia said they are in talks to buy
it.
Molnupiravir, on its way to be the first oral antiviral medication
for COVID-19, could halve the chances of dying or being hospitalized
for those most at risk of contracting severe COVID-19. Merck is
seeking approval by the U.S. Food and Drug Administration for the
pill.
The course of treatment involves patients taking four pills twice
daily for five days.
"We already have secured a budget enough for treatment of around
40,000 people and have signed a pre-purchase deal for 20,000
courses," Kim told a COVID-19 response meeting on Wednesday.
South Korea is also looking to buy other antiviral drugs, he said.
[to top of second column] |
Merck said it plans a tiered
pricing approach based on country income
criteria. The U.S. government has a contract to
buy 1.7 million courses at a price of $700 per
course.
The Korea Disease Control and Prevention Agency
(KDCA) had said it was also in talks with Pfizer
and Swiss drugmaker Roche Holding AG, who are
also racing to develop an easy-to-administer
antiviral pill
https://www.reuters.com/business/
healthcare-pharmaceuticals/covid-19-pill-developers-aim-top-merck-pfizer-efforts-2021-09-28
for COVID-19.
South Korean government had allocated 36.2
billion won ($30.31 million) in budget for oral
antiviral pills to cure COVID-19. It has been
managing its mortality rate - 0.78% as of
Tuesday - and critical cases at a fairly low
rate.
($1 = 1,194.2300 won)
(Reporting by Sangmi Cha; Editing by Simon
Cameron-Moore)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content |